Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.61 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.44 |
| ▸ | FNTB | P49356 | 2/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 5/20 | 0.38 |
| ▸ | NPY1R | P25929 | 4/20 | 0.38 |
| ▸ | NPY2R | P49146 | 4/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20179354 | 0.96 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FNTA | |
| Glutathione SCHEMBL16739379 | 0.91 | PTGS1 (0.76) | PTGS1GSTK1GLO1NOD1FNTA | |
| Glutathione SCHEMBL16739377 | 0.91 | PTGS1 (0.76) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL29498231 | 0.90 | PTGS1 (0.53) | PTGS1GSTK1GLO1FNTAFNTB | |
| SCHEMBL30897316 | 0.89 | PTGS1 (0.52) | PTGS1GSTK1GLO1FNTAFNTB | |
| SCHEMBL31391130 | 0.87 | PTGS1 (0.50) | PTGS1GSTK1GLO1NPY4RNPY1R | |
| Glutathione SCHEMBL17165667 | 0.85 | PTGS1 (0.74) | PTGS1GSTK1GLO1NOD1FNTA | |
| Glutathione SCHEMBL17165670 | 0.85 | PTGS1 (0.74) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL20179364 | 0.85 | PTGS1 (0.64) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL21578372 | 0.85 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976101-B2 | Multi-level specific targeting of cancer cells | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230165929-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONS | RENOVION, INC. | 2023-06-01 | — | — | US | disclosed |
| US-11602555-B2 | Treatment of respiratory tract diseases and infections with ascorbic acid compositions | RENOVION, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| US-20190351005-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONS | RENOVION, INC. | 2019-11-21 | — | — | US | disclosed |
| WO-2018094278-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH GLUTATHIONE COMPOSITIONS | RENOVION, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165929-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONS | GPX1, GPX4, GSR | PTGS1 194/4885GSTK1 8/4885GLO1 22/4885 |
| US-11602555-B2 | Treatment of respiratory tract diseases and infections with ascorbic acid compositions | GPX1, GPX4, GSR | PTGS1 194/4885GSTK1 8/4885GLO1 22/4885 |
| US-20190351005-A1 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONS | GPX1, GPX4, GSR | PTGS1 194/4885GSTK1 8/4885GLO1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.